BioSpace News Archive

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) and the Ontario Pharmacists Association (OPA) are pleased to announce the finalized partnership agreement to promote HealthTab™, a point-of-care blood screening tool for pharmacies.

Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced it has expanded its executive leadership team by adding Andrew Macan as its new Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary effective January 21, 2020.

Zymergen, a science and material innovation company, today announced that it has appointed Jay Flatley, Chairman of the Board of Illumina, and Sandra E. Peterson, former Group Worldwide Chairman for Johnson & Johnson, to the Company’s Board of Directors, effective immediately.

Eli Lilly and Company (NYSE: LLY), a global healthcare and biopharmaceutical company, will invest over $470 million and create more than 460 new jobs in Durham, Governor Roy Cooper announced today.

Quarterly Earnings Release Webcast

Funded in Part by Generous Community Members, Expansion Will Help Meet Demand for Expert Heart Care [21-January-2020] MORRISTOWN, N.J. , Jan. 21, 2020 /PRNewswire/ -- Atlantic Health System’s Morristown Medical Center, nationally recognized for heart care, today opened the second of two new 36-bed units for patients with heart disease, completing a two-story expansion

Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Fourth Quarter 2019 Financial Results on Thursday, February 6, 2020, at 4:30pm Eastern Time.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved TEPEZZATM (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). TEPEZZA is the first and only FDA-approved medicine for the treatment of TED

Cell>Point announced, based on its sponsored chelator and therapeutic research conducted at the University of Texas M.D. Anderson Cancer Center on Platinum-Oncardia and 177Lu-Oncardia, and the positive results of its lung cancer imaging trials with 99mTc-Oncardia®, that it will be moving forward with these two intra-nuclear therapeutics expanding its focus in theranostic medicine.

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, announced it will report financial results for the fourth quarter and full year 2019 after market close on Thursday, February 13, 2020.